Rb2/p130基因编码蛋白在非小细胞肺癌中的表达及临床意义

Expression of protein encoded by Rb2/p130 gene and its clinical significance in patients with non-small cell lung cancer

目的:联合检测Rb2/p130、p53和p21基因编码蛋白在非小细胞肺癌中的表达,分析其与预后的关系。方法:采用免疫组织化学方法,检测87例非小细胞肺癌病人的手术标本Rb2/p130、p53和p21基因编码蛋白的表达,并与病理组织学、临床分期、生存时间进行统计学分析。结果:Rb2/p130和p21蛋白表达阴性者分别为34例(39.1%)和42例(48.3%)。p53蛋白阳性表达者为45例(51.7%)。Rb2/p130表达缺失与肿瘤分化程度、临床分期均呈负相关(P<0.05)。p53表达阳性率与肿瘤分化程度相关(P<0.05),与临床分期无关。p53表达和Rb2/p130表达负相关,同时p53表达阳性和Rb2/p130表达缺失者预后差,术后生存期短(P<0.05)。结论:在非小细胞肺癌中,Rb2/p130表达缺失和p53表达阳性提示恶性程度高,同时检测p53和Rb2/p130的表达对判断非小细胞肺癌的预后可能具有一定的临床意义。

Objective：To determine the expressions of proteins encoded by p53, p21, and Rb2/p130 genes in patients with non-small cell lung cancer （NSCLC） and explore the relationship between their expressions and the prognosis of NSCLC. Methods：The expressions of p53, p21, and Rb2/pl30 proteins were determined by immunohistochemical method in 87 patients with NSCLC,and the relationships between their expressions and the pathological types, clinical stages, and survival time were analyzed. Results：The expressions of Rb2/p130 and p21 proteins were negative in 39.1%（34/87 ）and 48.3%（42/87 ） of the patients, respectively. The expression of p53 protein was positive in 51.7%（45/87） of the patients, The absent expression of Rb2/p130 protein was negatively conelated with the differentiated grades and clinical stages（P 〈 0.05）. The positive expression of p53 protein was negatively correlated with the differentiated grades（P 〈 0.05）, not the clinical stages. The survival time of patients with positive expression of p53 protein and absent expression of Rb2/p130 protein was shorter （P 〈 0.05）. Conclusion：The positive expression of p53 protein and absent expression of Rb2/p130 protein may predict the high mali malignant degree and poor prognosis in patients with NSCLC.